menu
    • menu
    [{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Dotinurad","moa":"Urate transporter","graph1":"Rheumatology","graph2":"Phase III","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"","sponsorNew":"Fuji Yakuhin \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Fuji Yakuhin \/ Eisai"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Fortress Biotech","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Dotinurad","moa":"URAT1","graph1":"Rheumatology","graph2":"Approved","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fuji Yakuhin \/ Fortress Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Fuji Yakuhin \/ Fortress Biotech"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Fortress Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dotinurad","moa":"URAT1","graph1":"Rheumatology","graph2":"Approved","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fuji Yakuhin \/ Fuji Yakuhin","highestDevelopmentStatusID":"12","companyTruncated":"Fuji Yakuhin \/ Fuji Yakuhin"},{"orgOrder":0,"company":"Fuji Yakuhin","sponsor":"Urica Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Dotinurad","moa":"","graph1":"Rheumatology","graph2":"Approved","graph3":"Fuji Yakuhin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fuji Yakuhin \/ Urica Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Fuji Yakuhin \/ Urica Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Fuji Yakuhin

    Menu

    Fuji Yakuhin

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Fuji Yakuhin

                            Japan arrow
                            CPhI India 2024
                            Not Confirmed

                            Fuji Yakuhin

                            Japan arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Approved

                            Sponsor : Urica Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Addi...

                            Details : Urece (dotinurad) is a potential best-in-class urate transporter inhibitor that is currently in Phase 1 clinical trial and being developed for the treatment of gout. It can lower blood uric acid levels by selectively inhibiting URAT1 and uric acid reabso...

                            Brand Name : Urece

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 14, 2022

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Approved

                            Sponsor : Urica Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Fuji Yakuhin

                            Japan arrow
                            CPhI India 2024
                            Not Confirmed

                            Fuji Yakuhin

                            Japan arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Approved

                            Recipient : Fortress Biotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatmen...

                            Details : Dotinurad (URECE® tablet) was approved in Japan in 2020 as a once-daily oral therapy for gout and hyperuricemia. Dotinurad was efficacious and well-tolerated in more than 500 Japanese patients treated for up to 58 weeks in Phase 3 clinical trials.

                            Brand Name : Urece

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 31, 2022

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Approved

                            Recipient : Fortress Biotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Fuji Yakuhin

                            Japan arrow
                            CPhI India 2024
                            Not Confirmed

                            Fuji Yakuhin

                            Japan arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved

                            Sponsor : Fortress Biotech

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America...

                            Details : Dotinurad is a potential best-in-class urate transporter (URAT1) inhibitor that was approved for the treatment of gout and hyperuricemia in Japan in 2020.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 10, 2021

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved

                            Sponsor : Fortress Biotech

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Fuji Yakuhin

                            Japan arrow
                            CPhI India 2024
                            Not Confirmed

                            Fuji Yakuhin

                            Japan arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase III

                            Sponsor : Eisai

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Eisai and FUJI YAKUHIN Conclude License Agreement

                            Details : Under this agreement, Eisai will proceed with the development of dotinurad in China.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 25, 2020

                            Lead Product(s) : Dotinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase III

                            Sponsor : Eisai

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth